Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Large-cell Lymphoma: early-phase trial registry
1 of 5 indexed Large-cell Lymphoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 1 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Large-cell Lymphoma: 5 US clinical trials tracked, 1 recruiting.
Large-cell Lymphoma is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Seagen, running 1 of these trials.
Enrollment posture brief
Registry condition large-cell-lymphoma
OPEN 1 | RECR 20% | LATE 0 | EARLY 3 | RANK #3391 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (20% recruiting · 10 trials)
Large-cell Lymphoma lists 1 open slots (20% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Large-cell Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Large-cell Lymphoma is recruiting below its size-band peers.
1 of 5 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Large-cell Lymphoma research.
Seagen accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.
-
Most Large-cell Lymphoma trials plan to enrol fewer than 100 people.
Median target enrolment is 48 among the 5 trials that report a genuine target (sentinel values excluded). 3 of those (60%) plan for fewer than 100 participants.
-
Large-cell Lymphoma research is mostly interventional.
4 interventional and 1 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
Memorial Sloan Kettering Cancer Center
NCT05940272
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers
Nkarta
NCT05020678
Telehealth-based Symptom Management for Veterans Treated With Selinexor
Durham VA Medical Center
NCT06452446
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
National Cancer Institute (NCI)
NCT02315612
Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma
Seagen
NCT00099255
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Large-cell Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Large-cell Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Large-cell Lymphoma page
5 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Large-cell Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Seagen sponsors the most Large-cell Lymphoma trials on record, review their full trial history before evaluating a specific study. See Seagen's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Large-cell Lymphoma condition card totals 5 registered trials; most-linked intervention SGN-30; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.